Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | PAM | P19021 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18650371 | 0.92 | MTNR1A (0.37) | TACR1MTNR1APAMKDM4EALDH1A1 | |
| SCHEMBL18650364 | 0.90 | ALDH1A1 (0.39) | TACR1MTNR1APAMKDM4EALDH1A1 | |
| SCHEMBL18650363 | 0.85 | CYP1A2 (0.31) | TACR1 | |
| SCHEMBL18650387 | 0.85 | ALDH1A1 (0.34) | ELANEKDM4EALDH1A1LMNATSHR | |
| SCHEMBL18650365 | 0.83 | GSTP1 (0.33) | ELANEALDH1A1 | |
| SCHEMBL18650377 | 0.79 | IDO1 (0.40) | — | |
| SCHEMBL18650352 | 0.78 | MAPT (0.34) | TACR1PAMKDM4EALDH1A1 | |
| SCHEMBL18653813 | 0.76 | TACR1 (0.38) | TACR1ELANEPAMALDH1A1LMNA | |
| SCHEMBL18655548 | 0.75 | IDO1 (0.36) | MTNR1A | |
| SCHEMBL18650385 | 0.75 | KDM4E (0.36) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630918-B2 | Cysteine, N-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-04-25 | — | — | US | disclosed |
| US-20170081280-A1 | CYSTEINE, N-ACETYLCYSTEINE, AND PENICILLAMINE RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081280-A1 | CYSTEINE, N-ACETYLCYSTEINE, AND PENICILLAMINE RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NAT1, HHAT, CBS | TACR1 1923/4885MTNR1A 940/4885ELANE 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.